The Role of Advanced Glycation End Products on Dyslipidemia
Аутори
Vekić, JelenaVujčić, Sanja
Bufan, Biljana
Bojanin, Dragana
Al-Hashmi, Khamis
Al-Rasadi, Khaild
Stoian, Anca Pantea
Zeljković, Aleksandra
Rizzo, Manfredi
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
Disorders of lipoprotein metabolism and glucose homeostasis are common consequences of insulin resistance and usually co-segregate in patients with metabolic syndrome and type 2 diabetes mellitus (DM). Insulin-resistant subjects are characterized by atherogenic dyslipidemia, a specific lipid pattern which includes hypertriglyceridemia, reduced high-density lipoprotein cholesterol level, and increased proportion of small, dense low-density lipoprotein (LDL). Chronic hyperglycemia favors the processes of non-enzymatic glycation, leading to the increased production of advanced glycation end products (AGEs). Apart from direct harmful effects, AGEs are also potent inducers of oxidative stress and inflammation. In addition, increased AGEs’ production may induce further qualitative modifications of small, dense LDL particles, converting them to glycated LDLs. These particles are even more atherogenic and may confer an increased cardiovascular risk. In this narrative review, we summarize the a...vailable evidence of the pathophysiological role and clinical importance of circulating AGEs and glycated LDLs in patients with dyslipidemia, particularly those with DM and related complications. In addition, we discuss recent advances and the issues that should be improved regarding laboratory assessment of AGEs and glycated LDLs, as well as the possibilities for their therapeutic modulation.
Кључне речи:
diabetes / AGEs / atherogenic dyslipidemia / glycated LDL / small, dense LDLИзвор:
Metabolites, 2023, 13, 1Издавач:
- MDPI
Финансирање / пројекти:
- Министарство науке, технолошког развоја и иновација Републике Србије, институционално финансирање - 200161 (Универзитет у Београду, Фармацеутски факултет) (RS-MESTD-inst-2020-200161)
DOI: 10.3390/metabo13010077
ISSN: 2218-1989
PubMed: 36677002
WoS: 000927623200001
Scopus: 2-s2.0-85146900900
Институција/група
PharmacyTY - JOUR AU - Vekić, Jelena AU - Vujčić, Sanja AU - Bufan, Biljana AU - Bojanin, Dragana AU - Al-Hashmi, Khamis AU - Al-Rasadi, Khaild AU - Stoian, Anca Pantea AU - Zeljković, Aleksandra AU - Rizzo, Manfredi PY - 2023 UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4415 AB - Disorders of lipoprotein metabolism and glucose homeostasis are common consequences of insulin resistance and usually co-segregate in patients with metabolic syndrome and type 2 diabetes mellitus (DM). Insulin-resistant subjects are characterized by atherogenic dyslipidemia, a specific lipid pattern which includes hypertriglyceridemia, reduced high-density lipoprotein cholesterol level, and increased proportion of small, dense low-density lipoprotein (LDL). Chronic hyperglycemia favors the processes of non-enzymatic glycation, leading to the increased production of advanced glycation end products (AGEs). Apart from direct harmful effects, AGEs are also potent inducers of oxidative stress and inflammation. In addition, increased AGEs’ production may induce further qualitative modifications of small, dense LDL particles, converting them to glycated LDLs. These particles are even more atherogenic and may confer an increased cardiovascular risk. In this narrative review, we summarize the available evidence of the pathophysiological role and clinical importance of circulating AGEs and glycated LDLs in patients with dyslipidemia, particularly those with DM and related complications. In addition, we discuss recent advances and the issues that should be improved regarding laboratory assessment of AGEs and glycated LDLs, as well as the possibilities for their therapeutic modulation. PB - MDPI T2 - Metabolites T1 - The Role of Advanced Glycation End Products on Dyslipidemia VL - 13 IS - 1 DO - 10.3390/metabo13010077 ER -
@article{ author = "Vekić, Jelena and Vujčić, Sanja and Bufan, Biljana and Bojanin, Dragana and Al-Hashmi, Khamis and Al-Rasadi, Khaild and Stoian, Anca Pantea and Zeljković, Aleksandra and Rizzo, Manfredi", year = "2023", abstract = "Disorders of lipoprotein metabolism and glucose homeostasis are common consequences of insulin resistance and usually co-segregate in patients with metabolic syndrome and type 2 diabetes mellitus (DM). Insulin-resistant subjects are characterized by atherogenic dyslipidemia, a specific lipid pattern which includes hypertriglyceridemia, reduced high-density lipoprotein cholesterol level, and increased proportion of small, dense low-density lipoprotein (LDL). Chronic hyperglycemia favors the processes of non-enzymatic glycation, leading to the increased production of advanced glycation end products (AGEs). Apart from direct harmful effects, AGEs are also potent inducers of oxidative stress and inflammation. In addition, increased AGEs’ production may induce further qualitative modifications of small, dense LDL particles, converting them to glycated LDLs. These particles are even more atherogenic and may confer an increased cardiovascular risk. In this narrative review, we summarize the available evidence of the pathophysiological role and clinical importance of circulating AGEs and glycated LDLs in patients with dyslipidemia, particularly those with DM and related complications. In addition, we discuss recent advances and the issues that should be improved regarding laboratory assessment of AGEs and glycated LDLs, as well as the possibilities for their therapeutic modulation.", publisher = "MDPI", journal = "Metabolites", title = "The Role of Advanced Glycation End Products on Dyslipidemia", volume = "13", number = "1", doi = "10.3390/metabo13010077" }
Vekić, J., Vujčić, S., Bufan, B., Bojanin, D., Al-Hashmi, K., Al-Rasadi, K., Stoian, A. P., Zeljković, A.,& Rizzo, M.. (2023). The Role of Advanced Glycation End Products on Dyslipidemia. in Metabolites MDPI., 13(1). https://doi.org/10.3390/metabo13010077
Vekić J, Vujčić S, Bufan B, Bojanin D, Al-Hashmi K, Al-Rasadi K, Stoian AP, Zeljković A, Rizzo M. The Role of Advanced Glycation End Products on Dyslipidemia. in Metabolites. 2023;13(1). doi:10.3390/metabo13010077 .
Vekić, Jelena, Vujčić, Sanja, Bufan, Biljana, Bojanin, Dragana, Al-Hashmi, Khamis, Al-Rasadi, Khaild, Stoian, Anca Pantea, Zeljković, Aleksandra, Rizzo, Manfredi, "The Role of Advanced Glycation End Products on Dyslipidemia" in Metabolites, 13, no. 1 (2023), https://doi.org/10.3390/metabo13010077 . .